Welcome to our dedicated page for Karuna Therapeutics news (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is an innovative clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for neuropsychiatric conditions with significant unmet medical needs. Our flagship product candidate, KarXT, is an oral modulator of muscarinic receptors, targeting both the central nervous system (CNS) and various peripheral tissues. KarXT uniquely combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.
Our pipeline capitalizes on the broad therapeutic potential of KarXT. We have assembled a team with extensive expertise in the research, development, and commercialization of CNS agents. This includes deep familiarity with the biology of neuropsychiatric disorders such as schizophrenia and Alzheimer's disease, and the role of muscarinic receptors in their potential treatment.
Recently, Karuna Therapeutics has achieved significant milestones in advancing KarXT through various stages of clinical trials, demonstrating promising results in improving symptoms of schizophrenia and other neuropsychiatric conditions. We are committed to leveraging our deep understanding of CNS biology to develop a pipeline of novel therapies aimed at addressing the pressing needs of patients with debilitating mental health conditions.
In addition to our scientific endeavors, we actively seek strategic partnerships and collaborations to accelerate the development and commercialization of our therapies. Our financial condition remains robust, supported by strategic investments and a clear focus on driving innovation in neuropsychiatric treatment.
Stay updated with the latest news and developments from Karuna Therapeutics, Inc. as we continue our mission to transform the treatment landscape for neuropsychiatric disorders.
Karuna Therapeutics (NASDAQ: KRTX) has initiated a public offering of $200.0 million in common stock, with an additional $30.0 million option for underwriters. The offering aims to raise funds through shares sold by the company itself. Goldman Sachs and J.P. Morgan are co-managing the offering, which will proceed subject to market conditions. All shares will be offered under a prior effective shelf registration statement with the SEC, and a preliminary prospectus will be filed shortly.
Karuna Therapeutics (NASDAQ: KRTX) announced Q4 and full-year 2020 financial results, reporting a net loss of $24 million for Q4 and $68.6 million for the year, up from $7.8 million and $44 million, respectively. Significant milestones included launching the Phase 3 EMERGENT program for KarXT in schizophrenia and filing for a new patent extending exclusivity through 2039. With $322.3 million in cash, the company projects it can fund operations into 2023, aiming to advance multiple clinical trials and potential NDA submissions.
Karuna Therapeutics announced the publication of results from the EMERGENT-1 Phase 2 clinical trial of KarXT for schizophrenia in the New England Journal of Medicine. The trial involved 182 participants and reported an 11.6-point reduction in the PANSS total score at Week 5 compared to placebo, with significant improvements noted in secondary outcome measures. KarXT was well-tolerated, with mild adverse effects, and did not cause common side effects associated with existing therapies. The results support advancing KarXT to Phase 3 trials, aiming to provide new treatment options for over 21 million individuals affected by schizophrenia globally.
Karuna Therapeutics, Inc. (NASDAQ:KRTX) will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 9:20 a.m. EST. The event highlights the company's commitment to developing transformative treatments for psychiatric and neurological conditions. A live webcast of the presentation will be accessible on the Investor Relations page of Karuna's website, with a replay available for 90 days thereafter. Karuna focuses on innovative neuroscience-based therapeutics, aiming to improve the lives of those affected by severe mental disorders.
Karuna Therapeutics (NASDAQ:KRTX) announced the appointment of Ronald Marcus, M.D., as Senior Vice President of Medical. Dr. Marcus brings over 30 years of experience in neuroscience drug development, including roles at Bristol-Meyers Squibb. His leadership will focus on advancing Karuna’s clinical pipeline, including the lead program, KarXT, aimed at treating schizophrenia and dementia-related psychosis. CEO Steve Paul emphasized Marcus' expertise as crucial for developing innovative neuropsychiatric therapies.
Karuna Therapeutics (NASDAQ: KRTX) announced that Andrew Miller, Ph.D., COO and founder, will speak at the ICR Conference 2021 on January 14, 2021, at 3:15 p.m. EST. The session will be accessible via a live webcast on Karuna's Investor Relations page. A replay of the event will be available for 90 days post-conference. Karuna is focused on developing innovative treatments for psychiatric and neurological conditions, emphasizing a need for effective solutions. For more details, visit www.karunatx.com.
Karuna Therapeutics (NASDAQ: KRTX) announced that CEO Steve Paul will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 10:50 a.m. EST. The presentation aims to showcase the company's commitment to developing transformative medicines for psychiatric and neurological conditions. Investors can access a live webcast of the event on Karuna’s Investor Relations page, with a replay available for 30 days post-conference. Karuna is focused on innovative treatments that address significant challenges faced by patients.
Karuna Therapeutics (NASDAQ: KRTX) announced the appointment of Denice Torres, J.D., to its Board of Directors, effective December 22, 2020. Torres brings over 25 years of healthcare and pharmaceutical experience, having held significant roles at Johnson & Johnson and Eli Lilly. Her leadership is expected to be instrumental as Karuna advances its Phase 3 clinical program targeting neuropsychiatric disorders. CEO Steve Paul highlighted her operational success and ability to foster diverse cultures as key assets during a critical growth phase for the company.
Karuna Therapeutics (NASDAQ: KRTX) has appointed Dr. David Wheadon to its Board of Directors and announced the upcoming resignation of Ed Harrigan, effective December 3, 2020. Dr. Wheadon brings over 30 years of experience in clinical development and regulatory affairs, previously serving at AstraZeneca. His expertise is expected to enhance Karuna's progression towards late-stage clinical development in neuropsychiatric therapies. Harrigan will transition to the scientific advisory board, ensuring continued contributions to the company's strategic direction.
KRTX, Karuna Therapeutics, will participate in the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. EST. This fireside chat will showcase insights from senior management on Karuna's mission to develop transformative therapies for neuropsychiatric disorders. Interested investors can watch the live webcast on the Investor Relations page of Karuna’s website, with a replay available for 90 days following the event. Karuna is focused on advancing treatment standards for CNS disorders, striving to improve the lives of affected individuals.
FAQ
What is the market cap of Karuna Therapeutics (KRTX)?
What is Karuna Therapeutics, Inc.?
What is KarXT?
What conditions does KarXT aim to treat?
What makes KarXT unique?
Who makes up the team at Karuna Therapeutics?
How is Karuna Therapeutics progressing with KarXT?
What is the financial condition of Karuna Therapeutics?
Does Karuna Therapeutics have any strategic partnerships?
Where can I find the latest news about Karuna Therapeutics?
What is the ticker symbol for Karuna Therapeutics, Inc.?
